Working together, companies offer enhanced abilities to monitor immunotherapy response in vaccine and drug studies.
Recently, it was announced that the Food and Drug Administration has approved a breakthrough cancer medication from Bristol-Myers Squibb Co. that researchers have heralded as the first drug shown to prolong the lives of patients with advanced skin cancer.
Readers gain an understanding of the details and the high level considerations of assay qualification for difficult cell-based assays. The level of optimization described for cell-based assays lends itself to biomarker assay automation which can be used for biomarker qualification and validation studies to the satisfaction of the FDA, EMEA, and other regulatory agencies.
Cell-based assay platforms covered are flow cytometry, intracellular cytokine ICS, immunophenotyping, elispot, IHC, cylex, neutralization bioassays, and endpoint assays.
IMMUNOSITE TECHNOLOGIES, LLC
P.O. Box 165937, Miami, FL 33116, USA
4981 SW 74 Court, Miami, FL 33155, USA
Telephone: (954) 462-6800
@2009 - 2018 ImmunoSite Technologies, LLC. All rights reserved.
